Moderna Earnings Beat, Stock Up 7.4% Over Flu Vaccine Snub
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Moderna posted a Q4 loss of $2.11 per share, narrowing from analysts’ $2.54 per share expectation.
- Moderna reported $678 million in revenue, surpassing the $635 million forecast.
- Moderna’s stock jumped 7.4% after earnings, continuing a 36% YTD rise fueled by a Phase 2b melanoma vaccine trial.
- Moderna reaffirmed its 2026 revenue growth target of 10%, above Wall Street’s ~6% projection.
- Moderna forecast $3 billion in R&D spending for 2026, in line with consensus estimates.
- FDA refused to review Moderna’s new seasonal flu vaccine, prompting a request for a Type A meeting.
- Moderna remains loss‑making, with 2025 revenue down to $1.9 billion from $19.3 billion in 2022 and no expected net profit until 2029.
Why it matters: Investors gain from the unexpected earnings beat and the 7.4% share rally, but the company’s persistent losses, a FDA’s refusal to review its new flu vaccine, and analysts’ view that profit won’t arrive until 2029 underscore heightened financial and regulatory risk for shareholders.
